NOVAVAX INC Finance Lease, Liability
NOVAVAX INC (NVAX) had Finance Lease, Liability of $4.60 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Debt
us-gaap:FinanceLeaseLiability · last filed 2026-02-26
- 2025-12-31: Finance Lease, Liability $4.60M.
- 2024-12-31: Finance Lease, Liability $60.73M.
- 2020-09-30: Finance Lease, Liability $118.96M.
| Period end | Finance Lease, Liability |
|---|---|
| 2025-12-31 | $4.60M 10-K · filed 2026-02-26 |
| 2024-12-31 | $60.73M 10-K · filed 2025-02-27 |
| 2020-09-30 | $118.96M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |